Glutamine-Dependent Biosynthetic Pathways Fuel Autoreactive T and B Cells in Foxp3 Deficiency-mediated Disease 2259241
Abstract
Abstract Introduction Foxp3 deficiency causes a profound loss of immune tolerance, unleashing autoreactive T and B cells, lymphoproliferation, cytokine-driven inflammation, and autoantibody production. This autoimmune pathology is fueled by increased glutamine usage, but it remains unresolved whether glutamine is necessary to produce energy, or for biosynthetic pathways leading to production of inflammatory modulators. Methods By using a Foxp3 deficiency model. Here, we demonstrate that glutamine utilization supports Foxp3-deficiency mediated disease independently of pathogenic Foxp3-deficient Treg cell energetic reprogramming Results Mechanistically, glutamine biosynthetic pathways sustain conventional T cell activation and proinflammatory cytokine production preventing inosine accumulation and signaling, thus implicating adenosine pathway modulation in autoreactive T cell dysregulation. Conversely, autoreactive B cell activation and autoantibody production depend on glutamine-dependent asparagine synthesis, which we reveal as a targetable vulnerability for autoantibody formation. Conclusion These findings highlight glutamine-driven biosynthetic processes as critical drivers of autoimmunity and reveal distinct metabolic vulnerabilities in autoreactive T and B cells that can be targeted for therapeutic intervention. Funding Source NIH NIAID Topic Categories Translational and Interventional Immunology (TI)
Article Details
Journal Info
The Journal of Immunology
American Association of Immunologists
Authors (12)
Mohammad Adeel Zafar
Boston Children’s Hospital, Harvard Med. School
Charlotte Nicole Hill Machado
Boston Children’s hospital, Harvard Medical School
Jyotirmaya Behera
Boston Children’s hospital, Harvard Medical School
Yuelin Zhong
Boston Children’s hospital
Xiao Li
Shakchhi Joshi
Blavatnik institute, Harvard Medical School
Yassine El Fazaa
Boston Children’s hospital
Virginia Camacho
1Boston Children's Hospital, Vascular Biology Program, Boston, United States
Peter Georgiev
Blavatnik Institute, Harvard Medical School
Marcia Haigis
Harvard Medical School
Kiran Kurmi
Blavatnik Institute, Harvard Medical School
Louis-Marie Charbonnier
Boston Children’s Hospital, Department of Pediatrics, Harvard Medical School